your initial deposit *subject to change and depends on individual circumstances.
Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for the development of next generation biologic drugs that extend the efficacy, safety and half-life of biologic drugs and OncoHist® for the...Read more
Xenetic Bioscience (OTCBB:GAIFD) chief executive Scott Maguire said he is "extremely excited" about the tie-up with healthcare giant Baxter, which has a headline value of US110mln, and its commitment to company. A total of US$10mln is being invested directly into Xenetic, which will make Baxter its second-largest shareholder.
13/02/2013Xenetic Biosciences One2One Investor Presentation 13th February 2013
08/11/2011Xenetic Biosciences One2One Presentation - 8th November 2011
23/09/2011Scott Maguire, CEO of Xenetic Biosciences, talks about David Cameron announcing this deal, Russia becoming a global biotech player, first such deal with a UK company, $19.5 million shares placed at a premium, 12 drug candidates, 3 layers of de-risking, an acquisition, & the Baxter relationship exceeding expectations.
Presentations & Company Media
Related Research & Media
No documents available.
Xenetic’s strategy as a Speciality Drug Developer has at its core the Company’s three patented drug delivery platforms that allow the creation of novel and next generation drug and vaccine candidates with applications over a broad range of therapeutic areas.
While proprietary drug development in the orphan drug sector will be a first priority, the Company will continue to seek out-licensing arrangements with leading Big Bio and Big Pharma partners for the development of novel or next generation therapeutics.
Xenetic has already established a clinical record for potential blockbuster candidates for the treatment of anaemia and diabetes; and, through its various development agreements in Russia, India and elsewhere (such as that established in 2006 with Baxter Healthcare) the Company believes that the dissemination, application and commercialisation of its technologies will be better facilitated by the outlicensing of multiple product candidates currently beyond its economic capacity to develop in-house.
PolyXen® is an enabling platform technology for protein drug delivery. It uses the natural polymer polysialic acid (PSA) to prolong the drug's half-life and potentially improve the stability of therapeutic peptides and proteins. Both the site of attachment and the length of the PSA chain can enhance the properties of the therapeutic by changing the apparent hydrodynamic radius of the molecule which, in turn, changes a number of the biological characteristics of the therapeutic. It can also be used for small molecule drugs.
Pre-clinical proof-of-concept studies and clinical studies in humans have shown that the key benefits of PolyXen for protein drug delivery may include:
- Preservation of drug functionality on conjugation
- Improved stability in vivo
- Prolonged pharmacological action
- Prolonged active life of the drug in the blood circulation
- Reduced frequency and amount of dosage
- Reduced immunogenicity and antigenicity
What is polysialic acid?
Polysialic acid (PSA) is a polymer chain comprised of sialic acids linked together. Sialic acid is found on the external membrane of a number of cell types in the body. In addition, it is a natural component expressed on the external membrane on a number of bacterial types. When used for therapeutic protein and peptide drug delivery, PSA provides a protective microenvironment following conjugation to the active drug. This increases the active half-life of the therapeutic drug in the body and allows it to exist largely undetected by the immune system.
For further information please click here
OncoHist™ is based on research related to the novel functions of histones. Histone H1 has strong anti-proliferative properties against cancer cells of different histological origin. This has been demonstrated extensively for hematologic malignancies, such as leukemias, lymphomas and myelomas, and also for tumors from other tissues. Susceptibility of cells to the cytotoxic effect of histones is determined by the ability of histone H1 to selectively destabilize the tumor cell membrane, which results in cell death.
OncoHist exhibits the same properties as naturally occurring histone H1.3 molecules and therefore has low immunogenicity and antigenicity. Extensive data suggest that OncoHist molecules have the ability to selectively destabilize the tumor cell membrane, which instigates cell death. The selective attack of the tumor cell membrane is due to OncoHist molecules ability to recognize the difference in membrane structure between tumor cells and their healthy counterparts.
OncoHist is being investigated for certain potential advantages over conventional cancer therapeutics in the areas of selectivity, toxicity, induction of resistance and immunogenicity.
A pilot clinical study (phase I/II) with Acute Myeloid Leukemia (AML) patients was performed at the Saarland University Hospital at Homburg/Saar, Germany. OncoHist was safe and well tolerated in this study. Clinical effects were noted in seven patients with three partial remissions. Most notably, two patients who received two treatment cycles each experienced stabilization of their disease for 7 and 17 months. A clinical trial of 120 AML patients is underway in the Russian Federation. This trial aims to examine the benefits of OncoHist in combination with standard therapy: cytarabine with mitoxantrone. An additional NHL trial has been initiated in Russia.
OncoHist has been granted orphan drug status for AML by both the FDA and EMA and for Acute Lymphocytic Leukemia (ALL) in Europe by the EMA.
Board of Directors
For further information please click here
Please click here for stock information
99 Hayden Ave, STE 230
Lexington, MA 02421
No info available.